Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GILEAD SCIENCES, INC.

(GILD)
  Report
Real-time Estimate Cboe BZX  -  11:17 2022-11-30 am EST
85.46 USD   -0.35%
07:59aEuropean Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy for the Treatment of HIV in Pediatric Populations
AQ
11/29Transcript : Gilead Sciences, Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 01:00 PM
CI
11/29Gilead Sciences Says EC Okays Low-Dose Tablet, Indication Extension for Biktarvy to Treat HIV in Pediatric Populations
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Gilead Sciences : Who owns the coronavirus cure China's move to patent Gilead's experimental drug for the novel virus could lead to legal wrangle

02/07/2020 | 11:59pm EST

China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights.

The state-backed Institute of Virology in Wuhan filed the patent for using remdesivir to fight the novel coronavirus on January 21, according to a statement posted on its website two weeks later on February 4. If approved, the drug will be used to facilitate its potential global market entry, it added.Studies have been conducted outside the human bodies and found that Gilead’s remdesivir compound and the off-patent chloroquine malaria drug are both “highly effective” in the control of coronavirus infection, the Wuhan institute and the Beijing Institute of Pharmacology and Toxicology said in a research published in Cell Research Journal.

“Since these compounds have [separately] been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease,” the researchers wrote.

The viral outbreak has triggered panic across the globe, forcing the nation to lock down Wuhan and other cities in central Hubei province where the deadly virus originated. It has also forced companies to shut their businesses in the mainland, forced border controls and rattled global markets.

President Xi Jinping said China must treat the fight against coronavirus as “the most important task at hand,” according to state broadcaster CCTV on February 3. So far, the virus has claimed more than 560 lives and infected at least 27,000 people, mostly in mainland China.

Remdesivir has not been approved anywhere globally and has not been showed to be safe or effective for any use, Gilead’s chief medical officer Merdad Parsey said in a statement on Friday.The firm is working with Chinese health authorities to conduct a clinical trial on patients with pneumonia symptoms to test its safety and efficacy, it said. Past clinical data on other coronaviruses give it “hope,” it added.

Medical workers transfer a suspected coronavirus patient to an ambulance from the World Dream cruise ship at Kai Tak Cruise Terminal in Hong Kong on February 3. Photo: Sam Tsang

China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights.The state-backed Institute of Virology in Wuhan filed the patent for using remdesivir to fight the novel coronavirus on January 21, according to a statement posted on its website two weeks later on February 4. If approved, the drug will be used to facilitate its potential global market entry, it added.Studies have been conducted outside the human bodies and found that Gilead’s remdesivir compound and the off-patent chloroquine malaria drug are both “highly effective” in the control of coronavirus infection, the Wuhan institute and the Beijing Institute of Pharmacology and Toxicology said in a research published in Cell Research Journal.

“Since these compounds have [separately] been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease,” the researchers wrote.

China to open second coronavirus hospital built in 10 days, with more beds than first

The viral outbreak has triggered panic across the globe, forcing the nation to lock down Wuhan and other cities in central Hubei province where the deadly virus originated. It has also forced companies to shut their businesses in the mainland, forced border controls and rattled global markets.

President Xi Jinping said China must treat the fight against coronavirus as “the most important task at hand,” according to state broadcaster CCTV on February 3. So far, the virus has claimed more than 560 lives and infected at least 27,000 people, mostly in mainland China.

Remdesivir has not been approved anywhere globally and has not been showed to be safe or effective for any use, Gilead’s chief medical officer Merdad Parsey said in a statement on Friday.The firm is working with Chinese health authorities to conduct a clinical trial on patients with pneumonia symptoms to test its safety and efficacy, it said. Past clinical data on other coronaviruses give it “hope,” it added.HK BUSINESS BRIEFINGGet updates direct to your inboxSUBSCRIBEBy registering, you agree to our TandC and Privacy Policy

A spokeswoman for the Foster City, California-based company said it had invented remdesivir, and had filed patent applications for the compound and its uses against coronaviruses globally, including in China, in 2016. The application in China is still pending.

“We are aware of reports of the Wuhan Institute for Virology’s patent application,” Sonia Choi, Gilead’s vice president of public affairs, said in an email reply to the South China Morning Post. “Our focus at this time is on rapidly determining the potential for remdesivir as a treatment for [the novel coronavirus] and accelerating manufacturing in anticipation of potential future supply needs.”

Asked if Gilead will contest the patent application filed by the Chinese researchers, she said China’s “application has been filed more than three years after Gilead’s filing and will be considered in view of what is already known about the compound and pending patent applications. We are unable to comment on details of [their] application because there is an 18-month delay for an application to be published.”Gilead filed a patent in 2016 for methods to treat coronavirus infections, without mentioning remdesivir. Its scientific findings on remdesivir’s effect on coronaviruses have been published in the Science Translational Medicine journal in June 2017 on how the drug, with the development code GS-5734, inhibits both epidemic and zoonotic coronaviruses.

The move by the Wuhan institute, the most advanced virology centre in Asia, evoked similar past acts elsewhere in the region. When Thailand decided in 2006 and 2007 to break patents on drugs to treat HIV and heart disease, foreign drugs makers including Abbott Laboratories responded by withdrawing their products for treating other diseases from the Southeast Asian country.

It is not know when the institute’s filing could be approved by China’s patent authority, but the unit of Chinese Academy of Sciences could provoke legal issues with its filing, according to Andrew Cobden, a patent and trademark lawyer in Hong Kong at Hogan Lovells in Hong Kong.

“One question is whether the specific combination of drugs or that specific medical use of the drug is novel, that is, the researchers who make a discovery have filed their patent application before it becomes known to the public,” Cobden said. “Another is whether they are inventive, that is, an ordinary researcher in this field would not have thought of combining those drugs, or using those drugs to treat the coronavirus.”

The Chinese researchers said the filing was based on “international practice” and for the “protection of national interest,” adding it will “temporarily not exercise any intellectual property rights if foreign pharmaceutical firms are willing to contribute towards combating the outbreak in China.”

Even if the Institute of Virology is granted the patent for the use of the drug on the novel coronavirus, it would not be able to get around any patents Gilead might have filed or obtained for the drug remdesivir, Cobden said. Gilead may as well choose to work with the institute to market the drug there.

“In theory, a patent owner may be able to use its patent to stop other companies from manufacturing, importing or selling that drug in China,” he said. “But a patent cannot stop doctors from prescribing the drug to treat a patient.”

It might take 12 to 18 months for the public to know the coverage of the patent applied for by the Wuhan institute when its application document is published, and the entire patent granting process could take several years, if its case falls within the industry norm, Cobden said.

© Pakistan Press International, source Asianet-Pakistan

All news about GILEAD SCIENCES, INC.
07:59aEuropean Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy for t..
AQ
11/29Transcript : Gilead Sciences, Inc. Presents at 5th Annual Evercore ISI Health..
CI
11/29Gilead Sciences Says EC Okays Low-Dose Tablet, Indication Extension for Biktarvy to Tre..
MT
11/29European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy« for ..
BU
11/29AstraZeneca boosts cancer portfolio with $320 mln Neogene deal
RE
11/28Gilead, Arcus Report Positive Update on Interim Analysis of Mid-Stage Lung Cancer Study
MT
11/18Factbox-Advertisers react to Twitter's new ownership
RE
11/15UK Drug Pricing Agency Rejects Merck & Co.'s Molnupiravir, Four Other COVID-19 Treatmen..
MT
11/15Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
RE
11/15Gilead Sciences to Present at Upcoming Investor Conferences
BU
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 26 521 M - -
Net income 2022 4 384 M - -
Net Debt 2022 15 970 M - -
P/E ratio 2022 23,8x
Yield 2022 3,40%
Capitalization 108 B 108 B -
EV / Sales 2022 4,66x
EV / Sales 2023 4,70x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 85,76 $
Average target price 81,29 $
Spread / Average Target -5,21%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.18.11%107 564
JOHNSON & JOHNSON2.93%460 384
ELI LILLY AND COMPANY32.42%345 817
ABBVIE INC.16.84%279 679
PFIZER, INC.-16.19%277 803
NOVO NORDISK A/S19.71%276 497